(MENAFN - AsiaNet News) B. Riley initiated coverage of PGEN with a 'Buy' rating and $12 target, implying more than 50% upside. MRNA touched a fresh 52-week high as Bernstein highlighted Intismeran ...
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.